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Abstract
Background: Associations between coping with and control over psychotic symptoms were
examined using the Maastricht Assessment of Coping Strategies-24, testing the hypothesis that the
cognitive domain of executive functioning predicted quality and quantity of coping.
Methods: MACS-24 was administered to 32 individuals with a diagnosis of schizophrenia. For each
of 24 symptoms, experience of distress, type of coping and the resulting degree of perceived
control were assessed. Coping types were reduced to two contrasting coping categories:
symptomatic coping (SC) and non-symptomatic coping (NSC; combining active problem solving,
passive illness behaviour, active problem avoiding, and passive problem avoiding). Cognitive
functioning was assessed using the GIT (Groninger Intelligence Test), the Zoo map (BADS:
Behavioural Assessment of Dysexecutive function), Stroop-test and Trail making.
Results: Cognitive function was not associated with frequency of coping, nor did cognitive function
differentially predict SC or NSC. Cognitive function similarly was not associated with symptom
distress or level of perceived control over the symptom.
Conclusion: There was no evidence that cognitive function predicts quantity or quality of coping
with symptoms in people with a diagnosis of schizophrenia. Variation in the realm of emotion
regulation and social cognition may be more predictive of coping with psychotic symptoms.
Background
How people cope with stress can reduce or amplify the
effects of adverse conditions on development of emo-
tional distress, but also on the development of psychiatric
disorders [1]. It has been suggested that subjects with a
diagnosis of schizophrenia employ a limited repertoire of
coping strategies with a preference for emotion-focused
strategies [1-5] which are regarded as less effective and
associated with worse outcomes [6]. It has been argued
that qualitative differences in coping strategies impact on
symptom severity, relapse prevention, social adaptation
and quality of life in subjects with a psychotic disorder [7-
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14] and may influence the probability of transition from
a prodromal or at risk mental state, to full blown disorder
with need for care [15].
According to the transactional analysis theory on coping,
stress is generated by the person's appraisal of the per-
sonal significance of potentially threatening or harmful
events and the success of subsequent attempts to cope
with perceived demands on that encounter [16]. For the
purpose of this paper, coping is defined as all behavioural,
emotional and cognitive strategies the person applies in
dealing with stress.
There is little work on the various cognitive processes
involved in selection of coping responses. Abilities as
inhibitory control, working memory, planning, strategic
thinking and attention, grouped together in the category
of executive function, enable self-regulatory behaviour in
people [17]. Especially executive functions are important
in eliciting coping when confronted with distress, corre-
lating with the degree in which a person perceives situa-
tional control [18]. Given the fact that individuals with a
diagnosis of schizophrenia show deficits in executive cog-
nitive function, it may be hypothesised that cognitive
impairment in schizophrenia is associated with less effec-
tive coping responses. Previous work in patients with
schizophrenia suggest that poor executive function and
mnemonic impairments may predict maladaptive coping
[19-21], associated with coping preferences characterised
by avoiding or ignoring [22-26]. Also, the ability to effec-
tively appraise and think about stressors is negatively
associated with cognitive deficits [27], which is a premise
of coping and may result in less effective coping
responses.
The above studies on coping and cognition in schizophre-
nia, however, used standard coping scales assessing gen-
eral coping responses with non-specific stress rather than
coping with psychotic symptoms and the associated expe-
rience of distress. The Maastricht Assessment of Coping
Strategies (MACS) is an instrument designed specifically
to assess coping with the symptoms that form part of the
diagnosis of schizophrenia [28]. An important difference
between MACS and other coping instruments is that the
focus of MACS is not on coping in general, but on coping
with specific symptoms in the context of a severe psychi-
atric illness. In this context, coping represents an essential
part of the treatment for psychotic disorder. A further dif-
ference is that the stressor, the psychotic symptom, is
socially stigmatised and that the patient, in order to
develop coping, must develop an accurate appraisal of the
symptom.
MACS assesses the level of distress associated with psy-
chotic symptoms, and 5 coping domains of active prob-
lem solving (APS), passive illness behaviour (PIB), active
problem avoiding (APA), passive problem avoiding
(PPA), and symptomatic coping behaviour (SCB)[28,29].
Symptomatic coping behaviour is defined as going along
with the content of the symptom [28,29]. Effectiveness of
coping in MACS is assessed by measuring the level of
"feeling in control" or perceived control experienced by
the person. This perceived control results from (i) moti-
vated behaviour associated with rewarding situations, (ii)
coping mechanisms in stressful situations and (iii) the
temperamental ability to switch attention or the propen-
sity to resolve conflicts by selecting to respond only to
those stimuli which will lead to reward and inhibit
responding to inappropriate or negative stimuli [18,30].
Previous work has shown that SC was negatively associ-
ated with perceived control over psychotic experiences
and also with an increase in risk of transition from pro-
dromal to clinical state. The other four coping domains,
however, were positively associated with perceived con-
trol, i.e. can be considered as effective strategies [15,28].
Previously, it has been argued that these four coping
domain could be usefully combined into one category of
coping, the category of Non-Symptomatic Coping (NSC;
for more detail about MACS see previous publica-
tions[15,28,31])
It was hypothesised that quantity and quality of coping
would be associated with better executive function. Is was
thus expected that i) executive dysfunction would be asso-
ciated with more distress and less perceived control, and
ii) that executive dysfunction would be associated with
less functional coping (more symptomatic and less non-
symptomatic coping).
Methods
Sample
Subjects were interviewed as part of the Experience Sam-
pling Method – Maastricht Assessment of Coping Strate-
gies (ESM-MACS) study. All subjects were born in the
Netherlands and fluent in Dutch. Thirty-four patients (21
men and 13 women) with a clinical DSM-IV [32] diagno-
sis of schizophrenia were interviewed by trained inter-
viewers at the level of psychologist with the MACS and the
Brief Psychiatric Rating Scale (BPRS), 24 item version
[33,34]. Mean age was 37.8 years (SD = 12.3, range 20–
68). All subjects received standard psychiatric care in var-
ious settings. Half of the sample was living in sheltered
housing outside the hospital, whereas the remaining 17
subjects lived alone (n = 8), with partner (n = 1) or with
parents (n = 8). One subject had regular employment, 2
subjects were retired and 31 (91%) were receiving disabil-
ity benefit. Nineteen subjects (62%) had received educa-
tion above secondary school. All subjects were in a stableBMC Psychiatry 2008, 8:39 http://www.biomedcentral.com/1471-244X/8/39
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phase, with no changes in medication, living situation or
service provision during the last six months.
The mean BPRS scores per symptom dimension (adjusted
for the number of BPRS items that made up the dimen-
sion) were: positive dimension: 1.5 (range 1 – 4), negative
dimension: 1.1 (range 1 – 2), depressive dimension: 1.6
(range 1 – 4.8) and excitement dimension: 1.2 (range 1 –
1.8).
The study was approved by Medical Ethics Committee of
the Academic Hospital Maastricht. People could only
enter the study after given written informed consent. They
could leave the study without declaration of any reason.
Assessment scales
Coping and psychopathology (MACS-24)
MACS-24 assesses coping in subjects with a psychotic dis-
order, focussing specifically on coping with symptoms
rather than with situations, and evaluating a range of pos-
sible different coping strategies for each symptom dimen-
sion.
Symptom dimensions – Five dimensions in subjects with
schizophrenia were conceptually derived from work
examining the BPRS, PANNS [35,36], PSE [37] and SENS
[38]. MACS-24 was designed to cover these five symptom
dimensions, with symptom descriptions based on symp-
tom definitions described in work using the BPRS,
PANNS, PSE and SENS. A prerequisite for the assessment
of coping with symptoms is that subjects have to be aware
of their symptoms. Therefore, some cognitive and nega-
tive symptoms, like abstract thinking, were excluded as
subjects are unable to produce conscious appraisals of
these [39,40]. Thus, a total of 24 symptoms were grouped
a priori in 5 dimensions of (I) positive symptoms (suspi-
ciousness, thought broadcasting, thought influence, gran-
diosity, magical thinking, passivity experiences, hearing
voices and non-verbal hallucinations), (II) negative symp-
toms (blunted affect, lack of initiative, emotional with-
drawal, and self-neglect), (III) depressive symptoms
(anxiety, somatic fixation, depressive mood and feelings
of guilt, lack of energy, diminished social contact), (IV)
cognitive symptoms (poor memory, poor attention and
concentration, slowed thinking and chaotic thinking), (V)
excitement (hostility and euphoria). MACS-24 was
designed to assess coping for each symptom. Individuals
are asked to indicate the level of distress they experience
in relation to each symptom on a 7-point Likert-scale
[28], followed by questions aimed at eliciting how indi-
viduals cope with symptom-related distress. Verbatim
responses are written down and coping is coded after-
wards by the interviewer according to the fourteen coping
categories described by Carr [28,29]. People are encour-
aged to be complete and include all the behavioural, emo-
tional and cognitive actions in response to the symptom
and associated distress. This open strategy (coping strate-
gies reported by the person) is used to avoid information
bias as a result of providing descriptions of specific coping
strategies [41]. After assessing the coping strategies, level
of perceived control over the symptom as a result of the
combined action of behavioural, emotional and cognitive
actions in response to the symptom and associated dis-
tress is assessed, providing a measure of the subjective
effectiveness of coping.
Cognitive tasks
Zoo Map (Behavioural Assessment of Dysexecutive Syndrome)
The Zoo Map is a subtest from the BADS, a test battery
designed for measurement of executive functions [42-44].
It is designed to assess difficulties due to executive deficits
patients encounter in every day life. Subjects are given a
map of a zoo and a set of instructions relating to places
they have to visit and rules they must follow. In the first
part of the test, the subject is required to plan a route
which enables them to visit all the places without break-
ing any rules. In the second part, the order in which places
should be visited is specified. The score on the first part of
the test was used, as this part involves planning and mon-
itoring of behaviour. The Dutch version of the BADS was
used [45]. The test-retest stability of this Dutch version
was 0.85 [46].
GIT (Groningen Intelligence Test)
The shortened version of the GIT was used as a measure of
general ability [47]. The GIT is a test of general intelligence
that is used in the Netherlands for purposes comparable
to the Wechsler Adult Intelligence Scale (WAIS) [48].
There is general agreement on which subtests are to be
used to arrive at good approximation of a full scale IQ
[47].
Stroop Color Word Test (SCWT)
This test involves selective attention, by displaying colour
names, coloured patches and colour names printed in
incongruously coloured ink [49]. The amount of extra
time needed to discard irrelevant but salient information
(verbal) in favour of less obvious aspects (colour naming)
is recorded [50]. For the current analysis, the time needed
to perform the third task (i.e., reading colour names
printed in incongruously coloured ink) was used (hereaf-
ter: Stroop interference)
Trail Making Test (TMT)
This test is used to measure visual conceptual and visuo-
motor tracking [51]. The TMT test consists of a part A,
which are 25 consecutively numbered circles to be con-
nected. Part B has 13 numbered circles and 13 circles with
the letters A through M, again to be connected but now
the task requires switching between numbers and letters.BMC Psychiatry 2008, 8:39 http://www.biomedcentral.com/1471-244X/8/39
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The B/A ratio of performance in the TMT provides a meas-
ure of executive function [52] (hereafter: TMT interfer-
ence).
Analyses
Of the 34 people who participated, 2 showed incomplete
data on MACS and the cognitive battery. Therefore, 32
subjects were used in this report. (See table 1)
Symptom level
The data were analysed with STATA, version 9.2 [53]. A
data file was constructed in which the 32 patients
included in the study contributed 768 observations: one
for each of the 24 symptoms described above (32 × 24 =
768 symptom observations). Each symptom pertained to
one of the 5 symptom dimensions as described above. In
the symptom-level analyses, dependent variables were
level of distress and level of control, and independent var-
iables were symptom dimensions and cognitive variables.
According to the hypotheses specified above, executive
dysfunction would be associated with more distress and
less perceived control.
Coping observation level
A data file was constructed where for each symptom the
scores of each of 14 coping strategies were scored, result-
ing in a data file with 32 (subjects) × 24 (symptoms) × 14
(coping strategies) = 10752 observations. Each coping
strategy pertained to one of 5 broader coping domains as
described above, which was further simplified to the two
domains of symptomatic and non-symptomatic coping as
described earlier. In the coping level analyses, the binary
coping variable (presence or absence of coping for the spe-
cific symptom and coping category) was the dependent
variable, and coping type, cognition, as well as their inter-
actions, were dependent variables. The interaction
between coping type and cognition was fitted as according
to the hypotheses specified above the impact of cognitive
impairment on quantity of coping would be evident for
functional coping, i.e. NSC, in particular.
As observations were clustered within individuals for both
data sets (symptom level and coping level), multilevel
random regression analyses were conducted using the
STATA XTGEE (binary coping variable) and XTREG (con-
tinuous distress and control variables) routines. For the
coping level analyses, effect sizes were expressed as odds
ratios (OR) with their 95% confidence interval (95%CI),
whilst for the symptom level analyses effect sizes were
expressed regression coefficients (B). Model contributions
of independent variables and interactions were assessed
by Wald test and, in the case of significant interaction,
stratified effect sizes were calculated as linear combina-
tions of main effects and interactions.
Results
Symptom level
The mean BPRS score was 31.7 (SD = 6.0, range 24 – 51).
Twenty one (66%) subjects were in symptomatic remis-
sion (i.e. meeting the psychopathology criterion but not
the time criterion of remission) as defined recently
[54,55]. However, symptomatic remission involves only
six of 24 BPRS items and does not exclude residual-level
symptomatology as typically seen in chronic patients.
Thus, all subjects had at least one symptom present per
MACS interview. The mean number of MACS symptoms
per subject was 7.0 (SD = 4.0, range 1 – 17) with a mean
distress score of 4.2 (SD = 1.9, range 1–7) and a mean
level of perceived control of 4.2 (SD = 1.9 range 1–7). The
mean number of MACS symptoms per subject was 7.0
(SD = 4.0, range 1 – 17) with a mean distress score of 4.2
(SD = 1.9, range 1–7) and a mean level of perceived con-
trol of 4.2 (SD = 1.9, range 1–7).
The mean IQ score was 101 (SD = 15.8, range 72 – 128),
the mean TMT interference score was 143 (SD = 402,
Table 1: Sample description
Total Men (n = 20) Women (n = 12)
Age (mean years) 35.9 (range 20–68) 31.6 (range 20–60) 44.9 (range 20–68)
Employment status:
Regular job 15% 16.3% 12.7%
No/Sheltered work 85% 83.7% 87.3%
Social:
Alone 24% 26.5% 18.8%
Partner 2% 0.0% 5.8%
Family/parents 33% 38.9% 20.9%
Sheltered living 41% 34.9% 55.0%
Level of education:
Primary school 22% 22.5% 20.3%
Secondary school 20% 21.1% 15.9%
Lower & Intermediate vocational education 43% 38.1% 52.2%
Higher vocational education & University 35% 18.4% 11.6%BMC Psychiatry 2008, 8:39 http://www.biomedcentral.com/1471-244X/8/39
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range -4 – 2315), the mean Stroop interference score was
126 (SD = 91, range 16 – 350) and the mean Zoo Map
score was 3.59 (SD 3.00, range 0 – 8).
Associations between distress, control and cognitive 
impairment
Apart from a weak negative association between experi-
ence of distress and IQ (B = -0.04; 95% CI: -0.06 – -0.01),
no associations were apparent with the other three cogni-
tive tests of TMT interference, STROOP interference and
Zoo Map. Perceived control was similarly not associated
with any of the four cognitive variables (See table 2).
Coping level
There were 373 instances of coping with the following dis-
tribution: active problem solving (APS): 22%, passive ill-
ness behaviour (PIB): 17%, active problem avoiding
(APA): 15%, passive problem avoiding (PPA): 19% and
symptomatic coping behaviour: 27%, indicating that the
group of Non-Symptomatic coping made up 73% of all
coping. (Table 3 displays the frequency per coping
domain). Instances of coping were distributed across
patients, only a single patient had no instances of coping
at all.
Associations with cognitive impairment
None of the four cognitive variables predicted coping
behaviour (IQ: OR = 1.01, 95% CI = 0.99 – 1.04; Trail-
making: OR = 0.99; 95% CI = 0.92 – 1.08; Zoo Map: OR
= 1.07, 95% CI = 0.91 – 1.25; Stroop: OR = 0.54; 95% CI
= 0.21 – 1.39). There was no evidence that the association
between cognition and coping was moderated by type of
coping (i.e. symptomatic or non-symptomatic) for Trail-
making, Zoo Map and IQ (p = 0.43, p = 0.69 and p =
0.051 respectively). Although there was evidence for such
an interaction for Stroop (p = 0.034), stratified analyses
revealed that the association with coping was non-signifi-
cant for both non-symptomatic (OR = 1.32, 95% CI =
0.88, 1.99) and symptomatic coping (OR = 0.56, 95% CI
= 0.27–1.16).
Discussion
It was hypothesised that quantity and quality of coping
would be positively associated with executive function; in
particular that cognitive impairment would be associated
with more distress and less perceived control, as well as
with less functional coping in people with a diagnosis of
schizophrenia. However, with the exception of an associ-
ation with IQ, which might have been arisen by chance,
there was no evidence that executive dysfunction was
associated with quality or quantity of coping.
The explanation for this finding may be related to the
characteristics of the MACS. The MACS differs from previ-
ous coping assessments in four ways: (i) the MACS exam-
ines coping with specific psychopathological symptoms
and associated distress rather than general coping strate-
gies, and (ii) the MACS focuses on descriptions of self-ini-
tiated coping, whereas in conventional coping
assessments discrepancies may arise between coping strat-
egies listed in the instrument and coping strategies that are
actually used as someone may use coping strategies with-
out recognising these as such [41], (iii) MACS assesses
coping only if patients are aware of symptoms and symp-
tom-related distress, as subjects need to recognise a symp-
tom and the associated distress experience to undertake
self-protective actions, (iv) perceived control is the out-
come variable of effectiveness of coping, that is the result
of a self-reported evaluation of the various coping strate-
gies used. MACS does not require insight, but awareness
of the experience, similar to an interview with any instru-
ment assessing psychopathology such as PANSS and
BPRS. MACS additionally requires that the patient is able
to reflect to a certain degree on what effects the symptom
has on him/her but for this no insight is required. There-
fore, in the MACS, unconscious coping strategies or so-
called "automatised" coping strategies people use in every
day life are excluded [56,57], as these are not considered
true coping strategies according to the definition used for
the purpose of these analyses.
It may be argued that this latter characteristic of the MACS
is relevant to the lack of any association with cognition in
the current study, as reduced awareness, to the degree that
it may be associated with poor insight, may be associated
with neurocognitive dysfunction, especially poorer execu-
tive function [58]. Therefore, the sample may have been
selected towards patients with awareness of symptoms
Table 2: Associations between 4 cognitive variables and symptom-related distress (distress experience), perceived control as the 
result of coping (perceived control), and frequency of symptomatic (symptomatic coping) and non-symptomatic coping (non-
symptomatic coping) to reduce distress
IQ TMT interference Stroop interference ZOO MAP
B 95%CI B 95%CI B 95%CI B 95%CI
Distress experience - 0.04 -0.06 - -0.12* -0.05 -0.16 – 0.05 0.79 -0.23 – 1.82 0.75 -0.08 – 0.23
Perceived control 0.03 -0.00 – 0.05 -0.01 -0.09 – 0.11 -0.17 -1.20 – 0.85 0.03 -0.14 – 0.19
* p < 0.05BMC Psychiatry 2008, 8:39 http://www.biomedcentral.com/1471-244X/8/39
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and better cognitive function. However, comparing the
neurocognitive findings with those of patients and con-
trols in previous studies in this area revealed that mean
performance in the current sample was comparable to
findings in chronic patients with schizophrenia and sub-
stantially lower than performance in control subjects. This
suggests that the sample was not selected towards better
cognitive functioning.
It has been argued, contrary to what is generally assumed,
that the pathway from stress to psychosis is not mediated
by cognitive impairment. Rather, there may be two inde-
pendent pathways, the first being characterised by cogni-
tive impairment and the second by abnormal affective
processes [59,60]. For example, it has been demonstrated
that the emotional reactivity to stress in the daily lives of
patients with schizophrenia is not the consequence of
cognitive impairment per se [61]. Elevated emotional
reactivity to stress was found in subjects vulnerable to psy-
chosis, suggesting that affective responses in the flow of
daily life are an indicator of genetic but also environmen-
tal liability to psychosis [60]. The affective state appears a
strong predictor of coping function [17,62], with negative
affect being associated with maladaptive coping [8] and
variation in emotional reactions to stressors being associ-
ated with coping dynamics [56,63,64]. Stress, in particular
states of negative affect, influences the efficiency of atten-
tional processes and the direction of selective attention.
The coping strategy chosen is likely to guide subsequent
selection, such that the coping strategy and selective atten-
tion are dynamically and reciprocally related [65].
Given the robust null finding with cognitive test variables,
there is little to suggest type II error. Nevertheless, the
MACS is a new instrument, which has not been used very
often and therefore may hold unknown insensitivities
with regard to cognitive associations. However, the focus
of MACS on authentic report of coping strategies comes
closest towards the original definition of coping [16]; it
does not incorporate information bias on coping strate-
gies, which is a problem for most other coping instru-
ments. Instead, it emphasises the fact that coping is a
conscious activity. As a result of this strict definition of
coping, only subjects who are aware of the symptom and
concomitant distress are able to reflect, in terms of coping,
on their symptoms and distress experience. This conserv-
ative definition excludes important areas of experience.
Further research with the MACS may contribute to a better
understanding of the specific qualities and pitfalls of the
MACS in coping research.
The majority of the sample was in a state of remission, but
patients in symptomatic remission may display coping for
residual symptoms. Thus, the analyses suggested that
instances of coping were distributed across patients as
only a single patient had no instances of coping at all. The
fact that the majority of the sample was in remission can-
not be taken to indicate that coping is not relevant in such
patients; research suggests that coping strategies are typi-
cally used in chronic patients with a degree of residual
symptoms, similar to the group in this study [66], and
that enhancing coping skills in this group may contribute
to better outcomes [67]. Although the mean BPRS score
Table 3: Frequency of coping per coping domain
Coping domain Coping strategy frequency %
Active Problem Solving (APS) Distraction 24 10.5
Problem solving 51 22.3
Help seeking 8 3.5
Passive Illness Behaviour (PIB) Physical change 48 21.1
Prescribed medication 9 3.9
Non-prescribed medication, drugs 8 3.5
Active Problem Avoiding (APA) Socialisation 10 4.4
Shifted attention 31 13.6
Task performing 6 2.6
Indulgence 9 3.9
Passive Problem Avoiding (PPA) Non-specific activities 29 12.7
Isolation 22 9.7
Suppression 19 8.3
Symptomatic Symptomatic behaviour 99 43.4
Total 373 11.7BMC Psychiatry 2008, 8:39 http://www.biomedcentral.com/1471-244X/8/39
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was low, it does not follow that executive function will be
better and associations with coping obscured, given the
fact that cognitive dysfunction is a stable feature that is
only weakly associated with symptomatology [68,69]. It
has been suggested that perceived control is the product of
motivated behaviour and emotion regulation capacities
[18]. In patients with a diagnosis of schizophrenia, coping
and perceived control are apparently entirely emotion reg-
ulated rather than guided by executive functions [18].
Therefore, this report disputes the association between
coping with symptoms and cognitive function, suggesting
that quantity and quality of coping with symptoms is part
of the affective pathway, independent from cognitive
function.
Limitations
The results of this study should be interpreted in the light
of the following limitations.
(i) The number of subjects was limited and therefore the
results should be seen as indications for future study
rather than conclusive findings; (ii) The group was rela-
tively homogenous. Therefore, differences in cognitive
functioning present in subgroups like first-episode
patients versus chronic patients or inpatients versus out-
patients remained unresolved with regard to differential
impact on coping properties and interactions with cogni-
tive functioning. (iii)
The mental effort people with a diagnosis of schizophre-
nia exhibit in test assessment, especially neurocognitive
batteries, is limited [70]. We did not control for this prob-
lem in our sample. (iv) While our a priori hypothesis
focussed on executive function, executive function is only
one of the domains of cognitive functioning. Therefore
one cannot extrapolate the results to general cognitive
dysfunction and coping in people with a diagnosis of
schizophrenia. (v) The test that was used to measure intel-
ligence (GIT) was an older version. Therefore, the norma-
tive data for this test tend to gave an overestimation of IQ
compared to other more recent intelligence tests (i.e. the
mean IQ of 101 we reported in this sample, would be
comparable with 93). This suggests we studied a repre-
sentative sample of chronic patients with a diagnosis of
schizophrenia. (vi) All subject were on antipsychotic med-
ication. We did not control for the effect of antipsychotic
medication, given the small sample size and the fact that
the direction of association between cognition and antip-
sychotic medication is not consistent. (vii) We cannot
exclude, on the basis of the current data, that those with
better cognitive functioning are better able to comply with
MACS procedures, in particular with regard to making
accurate appraisals of symptoms. (viii) Although it may
be argued that MACS requires that the patient is able to
reflect to a certain degree on what effects the symptom has
on him/her, this is not the same as requiring insight into
illness or the pathological nature of symptoms. (ix)
Finally, as mentioned in the discussion, the sample was
characterised by stable patients with few symptoms. We
cannot exclude that coping with weak symptoms requires
relatively little cognitive effort so that associations
between executive function and coping in the sample
would remain too low to be detected. Therefore, replica-
tion in a sample with more severe symptoms is required.
Conclusion
No evidence was found that coping in patients with a
diagnosis of schizophrenia was associated with cognitive
function. According the dynamic aspects of coping, use of
coping strategies are more likely to be emotion regulated.
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